Charts Suggest 2017 Will Be The Year Of Biotech
So far it appears that 2016 will go down in the books as a year of consolidation after a tremendous run for most of 2014-2015. In the article below, we’ll take a look at the charts and try to determine where prices are heading for the last couple months of 2016 and whether 2017 is going to be the year that bullish biotech investors have been patiently waiting for. (Check out: The Ups and Downs Of Biotechnology).
SPDR Biotech ETF
Investors who are seeking broad exposure to the biotech sector in the U.S. generally turn to exchange-traded products such as the SPDR Biotech ETF (XBI). In case you aren’t familiar, this fund is comprised of 87 holdings and has been designed to track the performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.
SPDR Biotech ETF
Investors who are seeking broad exposure to the biotech sector in the U.S. generally turn to exchange-traded products such as the SPDR Biotech ETF (XBI). In case you aren’t familiar, this fund is comprised of 87 holdings and has been designed to track the performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.